Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
5.57
+0.24 (4.50%)
Mar 9, 2026, 3:01 PM EDT - Market open
Immuneering Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
54
Market Cap
359.65M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| X4 Pharmaceuticals | 33.98M |
| Bicycle Therapeutics | 28.34M |
| Foghorn Therapeutics | 24.52M |
| Opus Genetics | 14.63M |
| Absci | 2.82M |
| Neurogene | 925.00K |
| Adlai Nortye | -1.35M |
IMRX News
- 3 days ago - Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 days ago - Immuneering to Present at the Leerink Global Healthcare Conference - GlobeNewsWire
- 18 days ago - Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 2 months ago - Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data - Seeking Alpha
- 2 months ago - Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower - Benzinga
- 2 months ago - Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript - Seeking Alpha
- 2 months ago - Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - GlobeNewsWire
- 2 months ago - Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 - GlobeNewsWire